CRYSTAL BROWN: Open Payments
NPI 1992162523 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,828 in 96 payments from 14 companies in 2025. Trend: 2023 $2,025 · 2024 $1,981 · 2025 $1,828
Food & beverage: $1,828
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 44 | $705 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $237 |
| Gilead Sciences, Inc. | 4 | $207 |
| Regeneron Healthcare Solutions, Inc. | 7 | $182 |
| Janssen Biotech, Inc. | 5 | $127 |
| Madrigal Pharmaceuticals | 3 | $92 |
| Aimmune Therapeutics, Inc. | 3 | $58 |
| Lilly USA, LLC | 3 | $47 |
| Ipsen Biopharmaceuticals, Inc | 2 | $40 |
| Intercept Pharmaceuticals, Inc. | 2 | $36 |
Products named: RINVOQ, ENTYVIO, DUPIXENT, CREON, Livdelzi, SKYRIZI, LINZESS, TREMFYA.
Industry payments across AR — which companies pay providers there.
